The data for this study is hosted by the Hong Kong Hospital Authority. Subject to local law and regulation regarding the use and distribution personal data, the database used in the present study cannot be deposited in public data repositories. Data can be applied through the Data Sharing Portal of the Hong Kong Hospital Authority (<https://www3.ha.org.hk/data/DCL/Index/>).

Introduction {#sec007}
============

Type 2 diabetes mellitus is a complex progressive disease of rapidly growing prevalence. The global prevalence of type 2 diabetes is currently estimated at 415 million and is projected to escalate to 642 million over the next 25 years \[[@pmed.1003052.ref001]\]. More than half of the world's population of those with type 2 diabetes comes from Asia, where rapid industrialisation and urbanisation have contributed to an obesogenic living environment and increasing rates of overweight and obesity \[[@pmed.1003052.ref001]\].

The majority of published population-based studies on the epidemiology of type 1 and type 2 diabetes in Asia, including China, reported prevalence data, but few examined the incidence of diabetes \[[@pmed.1003052.ref002],[@pmed.1003052.ref003]\]. Although the prevalence informs the disease burden, the incidence reflects how population exposure to risk factors has changed over time, and these estimates are necessary for the accurate projection of future prevalence. Importantly, disease incidence communicates to the health policy makers whether strategies to prevent diabetes have been effective. Recently, Quan and colleagues reported the incidence and prevalence of diabetes in Hong Kong and detected a decline in the incidence of diabetes over a 9-year period between 2006 and 2014 \[[@pmed.1003052.ref004]\]. However, diabetes types were not differentiated, and trends among the paediatric population were not explored. We accessed the territory-wide database hosted by the Hong Kong Hospital Authority (HA) and described the secular trends in incidence of type 1 and type 2 diabetes from 2002 to 2015.

Methods {#sec008}
=======

Setting {#sec009}
-------

Hong Kong is a special administrative region of People's Republic of China and has a population of 7.44 million. The Hong Kong HA is a statutory body formed in 1996 that governs all 47 public hospitals and 73 government outpatient clinics in Hong Kong. Because of the wide cost differential between public and private healthcare sectors, around 89% of the local residents receive care for chronic illnesses in the HA \[[@pmed.1003052.ref005]\]. A territory-wide electronic medical record system, adopted in 2000, captures demographic information, diagnostic and procedure codes, laboratory results, and drug prescriptions of people attending public hospitals and clinics.

Study population {#sec010}
----------------

The Hong Kong Diabetes Surveillance Database (HKDSD) is a population-based cohort of people with diabetes in Hong Kong identified from the HA electronic medical record system between 1 January 2000 and 31 December 2016. The analysis was not prespecified and was planned after obtaining and reviewing the content of the database. Diabetes was ascertained based on one or more of the following qualifying criteria: (1) glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol/mol) in any one available HbA1c measurement \[[@pmed.1003052.ref006]\]; (2) fasting plasma glucose (FPG) ≥ 7.0 mmol/L in any one available FPG measurement \[[@pmed.1003052.ref007]\]; (3) prescription of noninsulin antihyperglycaemic drugs and/or (4) prescription of insulin for at least 28 days continuously, with or without (5) recording of the diagnostic code of diabetes based on the *International Classification of Diseases*, *Ninth Revision* (ICD-9) code 250; and/or (6) recording of the diagnostic code of diabetes according to the revised edition of the *International Classification of Primary Care*, *World Organization of National Colleges*, *Academics*, *and Academic Associations of General Practitioners/Family Physicians* code T89 or code T90. To minimise misclassification of normal individuals as having diabetes, people who received diagnostic coding of diabetes but did not fulfil any of the laboratory or drug criteria throughout the observation are not considered. To avoid inclusion of women with gestational diabetes, we removed episodes occurring within 9 months prior to or 6 months after delivery (ICD-9 codes 72--75) or occurring within 9 months before or after any pregnancy-related encounter (ICD-9 codes 630--676). However, women with subsequent episodes that met the criteria for diabetes occurring outside the context of any obstetric events would be included.

The separation of diabetes types is not reliable based on coding alone in administrative databases. In the HKDSD, a small subset of people received ICD-9 coding for both type 1 and type 2 diabetes. For the purpose of this analysis, we developed and validated an algorithm to delineate type 1 from type 2 diabetes using another database, the Hong Kong Diabetes Register (HKDR). In brief, the HKDR contains clinical information on people with physician-diagnosed diabetes who were referred to two public hospitals (Prince of Wales Hospital and Alice Ho Miu Ling Nethersole Hospital) for assessment of diabetes complications. In the HKDR, diabetes subtype was determined by the referring physician and was independently confirmed with chart review by one of the investigators (CK) of the present study. Type 1 diabetes was defined as clinical presentation with diabetic ketoacidosis and/or continuous requirement of insulin within 1 year of diagnosis. Positivity for islet autoantibodies was not used to define autoimmune diabetes because antibodies were not routinely measured. Of 24,060 patients in the HKDR, we excluded people with onset dates outside of 1 January 2002 to 31 December 2015 (*n* = 8,403) and those with missing data on diabetes subtype (*n* = 357). Of the remaining 15,297 people with newly diagnosed diabetes, type 1 diabetes was confirmed in 103 patients. The cohort was separated in a 2:1 ratio for derivation and validation of the algorithm, respectively. We considered ICD-9 codes (type 1 diabetes: ICD-9 250.x1 or 250.x3, type 2 diabetes: ICD-9 250.x0 or 250.x2) and types of insulin treatment in the algorithms, and we tested 12 combinations for sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for identifying type 1 diabetes. Of these combinations, ratios of type 1 to type 2 diabetes codes ≥4 or prescription of a combination of short- and long-acting insulin and no noninsulin antihyperglycaemic treatment within the first year of diagnosis yielded the optimal sensitivity of 100.0% (95% CI 76.8--100.0), specificity of 100.0% (95% CI 87.2--100.0), PPV of 100.0% (95% CI 76.8--100.0), and NPV of 100.0% (95% CI 87.2--100.0) in the HKDR for people aged \<20 years in the validation cohort. The sensitivity and PPV of this algorithm for identifying type 1 diabetes decreased to 50.0%--71.4% and 28.6%--62.5%, respectively, in people aged ≥20 years, which is expected because of the rarity of type 1 diabetes at older ages.

Statistical analysis {#sec011}
--------------------

An incident case of diabetes was identified by the first occurrence of any episode fulfilling the definition of diabetes and at least 2 years of diabetes-free observation prior. At least 1 year of surveillance from the date of diagnosis was required to enable discrimination of type 1 and type 2 diabetes. Thus, although the database includes cases of diabetes from 1 January 2000 to 31 December 2016, incidence of diabetes was described from 1 January 2002 to 31 December 2015. The date of diagnosis was the date to first fulfil the qualifying event. We estimated sex-specific annual incidence rates of type 1 and type 2 diabetes. The numerator was the number of incident cases of diabetes in the HKDSD in each calendar year, and the denominator was the estimated Hong Kong population of the previous year at midyear as reported by the local census and statistics department. Calculated rates were expressed per 100,000 person-years. We reported age-standardised rates (using the age structure of the World Health Organization standard population) for the entire population and for subgroups by sex and age categories (\<20 years, 20 to \<40 years, 40 to \<60 years, ≥60 years). We calculated the annual percentage change (APC) and the average APC (AAPC) in incidence rates with 95% CI by sex and by age bands. Joinpoint regression analysis was used to describe incidence trends over time. The optimal number of line segments that best fit the pattern was identified, and APCs were computed for the slope before and after each joinpoint using regression analysis. Because of an observed irregularity in the number of new cases of type 2 diabetes in 2004, trend analysis including reporting of APC and AAPC for both type 2 and type 1 diabetes (for consistency) was restricted to the period between 1 January 2005 and 31 December 2015. In a sensitivity analysis, we conducted trend analysis for type 2 diabetes using restricted cubic spline, which allowed for a more flexible fitting of the change in incidence rates, and results are presented in the Supporting information. Statistical significance was set at *p*-value of \<0.05. Analysis was performed using SAS version 9.4 (Cary, NC) and Joinpoint Regression Program version 4.6.0.0 (National Cancer Institute, Bethesda, MD).

Results {#sec012}
=======

Of 778,051 people captured in the HKDSD, we excluded 33,916 people who had diabetes codes but did not fulfil other criteria of diabetes. We further excluded 137,569 cases of prevalent diabetes (episodes fulfilling diabetes between 1 January 2000 and 31 December 2001) and 44,544 cases of diabetes that occurred between 1 January 2016 and 31 December 2016. The remaining 562,022 people with incident type 1 or type 2 diabetes occurring between 2002 and 2015 were included in the analysis ([S1 Fig](#pmed.1003052.s003){ref-type="supplementary-material"}, [S1 Table](#pmed.1003052.s001){ref-type="supplementary-material"}). Demographic and clinical characteristics of the cohort at diagnosis are detailed in [S2 Table](#pmed.1003052.s002){ref-type="supplementary-material"}.

Trends in incidence of type 1 diabetes {#sec013}
--------------------------------------

Using the derived algorithm, 2,426 people with newly diagnosed diabetes were classified as having type 1 diabetes, among whom 774 (31.9%) were aged \<20 years and 845 (34.8%) and 807 (33.3%) were aged 20 to \<40 years and ≥40 years, respectively ([S1 Table](#pmed.1003052.s001){ref-type="supplementary-material"}). Age-standardised incidence of type 1 diabetes increased from 2005 to 2015 in people aged \<20 years in both sexes, from 3.5 (95% CI 2.2--4.9) to 5.3 (95% CI 3.4--7.1) per 100,000 person-years (AAPC 3.6% \[95% CI 0.2--7.1\], *p* \< 0.05) in boys and from 4.3 (95% CI 2.7--5.8) to 6.4 (95% CI 4.3--8.4) per 100,000 person-years (AAPC 4.7% \[95% CI 1.7--7.7\], *p* \< 0.05) in girls ([Table 1](#pmed.1003052.t001){ref-type="table"}). Broken down into narrower age bands, the incidence of type 1 diabetes peaked in the age groups of 5--9 years in the female sex and 10--14 years in the male sex and declined with increasing age. Among those aged 20 to \<40 years and ≥40 years, incidence of type 1 diabetes remained stable over time ([Table 1](#pmed.1003052.t001){ref-type="table"}). Sex differences in the risk of type 1 diabetes were detected in the people aged \<20 years but not in people aged ≥20 years. The rate ratio for type 1 diabetes was 1.38 (95% CI 1.10--1.37, *p* \< 0.05) in girls compared with boys.

10.1371/journal.pmed.1003052.t001

###### Joinpoint analysis of the trend in incidence of type 1 and type 2 diabetes in Hong Kong Chinese stratified by sex and age groups between 2005 and 2015.

![](pmed.1003052.t001){#pmed.1003052.t001g}

  Age and sex categories   2005--2015           Time period 1   Time period 1                                                                       
  ------------------------ -------------------- --------------- --------------- ---------------------- -------- ------------ ---------------------- --------
  Type 1 diabetes                                                                                                                                   
   Age \<20 years                                                                                                                                   
    Boys                   3.6 (0.2--7.1)       \<0.05          2005--2013      1.5 (−4.7 to 8.0)      0.59     2013--2015   17.3 (−30.4 to 97.5)   0.48
    Girls                  4.7 (1.7--7.7)       \<0.05          2005--2008      8.7 (−11.9 to 34.2)    0.37     2008--2015   3.6 (−1.8 to 9.2)      0.16
   Age 20 to \<40 years                                                                                                                             
    Men                    −1.8 (−6.1 to 2.7)   0.39            2005--2015      −1.8 (−6.1 to 2.7)     0.39                                         
    Women                  −0.8 (−5.7 to 4.3)   0.72            2005--2015      −0.8 (−5.7 to 4.3)     0.72                                         
   Age 40 to \<60 years                                                                                                                             
    Men                    −1.7 (−6.7 to 3.6)   0.48            2005--2015      −1.7 (−6.7 to 3.6)     0.48                                         
    Women                  1.1 (−5.5 to 8.2)    0.72            2005--2015      1.1 (−5.5 to 8.2)      0.72                                         
   Age ≥60 years                                                                                                                                    
    Men                    1.2 (−6.1 to 9.1)    0.73            2005--2015      1.2 (−6.1 to 9.1)      0.73                                         
    Women                  −2.2 (−9.8 to 6.0)   0.55            2005--2015      −2.2 (−9.8 to 6.0)     0.55                                         
  Type 2 diabetes                                                                                                                                   
   Age \<20 years                                                                                                                                   
    Boys                   5.9 (3.4--8.5)       \<0.05          2005--2008      0.8 (−15.1 to 19.6)    0.92     2008--2015   7.5 (2.9--12.4)        \<0.05
    Girls                  4.8 (2.7--7.0)       \<0.05          2005--2008      −2.1 (−15.5 to 13.4)   0.73     2008--2015   7.1 (3.0--11.2)        \<0.05
   Age 20 to \<40 years                                                                                                                             
    Men                    4.2 (3.1--5.3)       \<0.05          2005--2008      8.8 (4.8--13.0)        \<0.05   2005--2015   2.2 (1.3--3.2)         \<0.05
    Women                  3.3 (2.3--4.2)       \<0.05          2005--2010      4.6 (2.8--6.4)         \<0.05   2010--2015   2.0 (0.4--3.6)         \<0.05
   Age 40 to \<60 years                                                                                                                             
    Men                    2.1 (0.7--3.6)       \<0.05          2005--2012      3.9 (2.4--5.4)         \<0.05   2012--2015   −1.9 (−6.7 to 3.1)     0.37
    Women                  0.5 (−1.4 to 2.3)    0.63            2005--2011      2.7 (0.1--5.3)         \<0.05   2011--2015   −2.8 (−6.9 to 1.5)     0.16
   Age ≥60 years                                                                                                                                    
    Men                    −0.1 (−1.8 to 1.6)   0.88            2005--2015      −0.1 (−1.8 to 1.6)     0.88                                         
    Women                  −1.7 (−3.9 to 0.5)   0.12            2005--2011      1.1 (−1.8 to 4.2)      0.39     2011--2015   −5.8 (−10.6 to −0.8)   \<0.05

Abbreviations: AAPC, average annual percentage change; APC, annual percentage change

Trends in incidence of type 2 diabetes {#sec014}
--------------------------------------

Among 559,596 incident cases of type 2 diabetes, 1,182 (0.2%) presented below 20 years of age, 22,924 (4.1%) presented in people aged 20 to \<40 years, and 535,490 presented (95.7%) in people aged ≥40 years ([S1 Table](#pmed.1003052.s001){ref-type="supplementary-material"}). The incidence rose with age and peaked in the age groups of 65--75 years in both men and women ([Fig 1](#pmed.1003052.g001){ref-type="fig"}). A transient increase in the number of incident cases of type 2 diabetes was recorded in 2004. The number of new cases was 34,921 in 2002, 37,229 in 2003, 58,375 in 2004, 33,759 in 2005, and 31,061 in 2006 ([S1 Table](#pmed.1003052.s001){ref-type="supplementary-material"}, [S2 Fig](#pmed.1003052.s004){ref-type="supplementary-material"}). The majority (76.2%) of the new episodes of type 2 diabetes in 2004 was identified by first-time use of noninsulin antihyperglycaemic drugs alone, suggesting that these occurrences could be prevalent cases initially diagnosed and followed outside of HA and later presenting to HA for continuation of existing treatment. Incident cases captured in 2004 or before were excluded from subsequent trend analysis.

![Incidence of type 2 diabetes in Hong Kong Chinese men (A) and women (B) by age stratified by the following calendar periods: 2006--2009, 2010--2013, and 2014--2015.](pmed.1003052.g001){#pmed.1003052.g001}

An increase in the incidence of type 2 diabetes was observed in the \<20 years and 20 to \<40 years age groups ([Table 1](#pmed.1003052.t001){ref-type="table"}, [Fig 2A and 2B](#pmed.1003052.g002){ref-type="fig"}). For people \<20 years old, the age-standardised incidence of type 2 diabetes increased from 4.6 (95% CI 3.2--6.0) to 7.5 (95% CI 5.5--9.6) per 100,000 person-years (AAPC 5.9% \[95% CI 3.4--8.5\], *p* \< 0.05) in boys and from 5.9 (95% CI 4.3--7.6) to 8.5 (95% CI 6.2--10.8) per 100,000 person-years (AAPC 4.8% \[95% CI 2.7--7.0\], *p* \< 0.05) in girls ([Table 1](#pmed.1003052.t001){ref-type="table"}) from 2005 to 2015. For people 20 to \<40 years old, we identified a greater increase in the incidence of type 2 diabetes before 2010 in women and before 2008 in men, after which the ascending trend slowed down. In men, the incidence increased from 75.4 (95% CI 70.1--80.7) to 94.4 (95% CI 88.3--100.5) per 100,000 person-years (APC 8.8% \[95% CI 4.8--13.0\], *p* \< 0.05) between 2005 and 2008 and from 94.4 (95% CI 88.3--100.5) to 110.8 (95% CI 104.1--117.5) per 100,000 person-years (APC 2.2% \[95% CI 1.3--3.2\], *p* \< 0.05) between 2008 and 2015. In women, the incidence increased from 45.0 (95% CI 41.4--48.6) to 55.1 (95% CI 51.0--59.1) per 100,000 person-years (APC 4.6% \[95% CI 2.8--6.4\], *p* \< 0.05) between 2005 and 2010 and from 55.1 (95% CI 51.0--59.1) to 62.1 (95% CI 57.8--66.3) per 100,000 person-years (APC 2.0% \[95% CI 0.4--3.6\], *p* \< 0.05) between 2010 and 2015. The AAPCs were 4.2% (95% CI 3.1--5.3) and 3.3% (95% CI 2.3--4.2) in men and women, respectively, for the entire period (*p* \< 0.05). The sex disparity in incidence of type 2 diabetes varied by age. For people \<20 years old, the incidence was disproportionately higher in girls than in boys, with an overall rate ratio of 1.22 (95% CI 1.10--1.37, *p* \< 0.05). Upon reaching young adulthood, the risk reversed, and men had higher incidence rates than women.

![Age-standardised incidence of type 2 diabetes in Hong Kong Chinese aged \<20 years (A), 20 to \<40 years, (B) and ≥40 years (C) between 2002 and 2015.](pmed.1003052.g002){#pmed.1003052.g002}

In people aged 40 to \<60 years, we detected an initial increase in incidence followed by stabilisation in both sexes ([Table 1](#pmed.1003052.t001){ref-type="table"}, [Fig 2C](#pmed.1003052.g002){ref-type="fig"}). In men, the incidence of type 2 diabetes increased from 697.0 (95% CI 681.1--712.8) to 852.7 (95% CI 836.0--869.3) per 100,000 person-years between 2005 and 2012 (APC 3.9% \[95% CI 2.4--5.4\], *p* \< 0.05) and was constant until 2015 (APC −1.9% \[95% CI −6.7 to 3.1\], *p* = 0.37). In women, the incidence increased from 569.7 (95% CI 555.3--584.0) to 639.8 (95% CI 601.8--628.5) per 100,000 person-years between 2005 and 2011 (APC 2.7% \[95% CI 0.1--5.3\], *p* \< 0.05) and had no significant change thereafter (APC −2.8% \[95% CI −6.9 to 1.5\], *p* = 0.16). Among people aged ≥60 years, the incidence was stable between 2005 and 2011 (APC 1.1% \[95% CI −1.8 to 4.2\], *p* = 0.39), followed by a decline (APC −5.8% \[95% CI −10.6 to −0.8\], *p* \< 0.05) in women, whereas in men, the incidence of type 2 diabetes was unchanged across the observation period. Trend analyses using restricted cubic splines are presented in [S3 Fig](#pmed.1003052.s005){ref-type="supplementary-material"}.

We determined the HbA1c levels at diagnosis of diabetes among people who were diagnosed using HbA1c criteria ([S4 Fig](#pmed.1003052.s006){ref-type="supplementary-material"}). Between 2002 and 2011, HbA1c levels at diagnosis of diabetes decreased from 8.5% to 8.0% (*p* \< 0.05 for a linear trend) in men and from 8.1% to 7.6% (*p* \< 0.05 for a linear trend) in women. From 2011 to 2015, however, the HbA1c levels at diagnosis remained static in both sexes.

Discussion {#sec015}
==========

Using the territory-wide HKDSD, we conducted time trend analyses on the incidence of type 1 and type 2 diabetes in people in Hong Kong. Between 2005 and 2015, the incidence of type 2 diabetes increased in people aged \<20 years and 20 to \<40 years, increased and then stabilised in people aged 40 to \<60 years, and was unchanged in those aged ≥60 years. Incidence of type 1 diabetes continued to climb in people aged \<20 years but remained constant in other age groups. Although the incidence of type 1 diabetes was the highest in those \<20 years old, adult-onset type 1 diabetes accounted for over two-thirds of newly diagnosed cases during the surveillance period. Among those \<20 years old, type 2 diabetes contributed to more than half of the newly presented cases. The key strengths of this study were the use of population-level data through access to the electronic medical record system of the Hong Kong HA and its low susceptibility to selection bias. Given the scarcity of population-level data on secular changes in diabetes incidence in Asia, our results are timely in providing insights into the contemporary diabetes epidemic in this region. Importantly, this study highlights the emerging problem of young-onset diabetes and calls for effective strategies to reduce modifiable risk factors for diabetes in this group.

Incidence of type 1 diabetes {#sec016}
----------------------------

The multinational European Diabetes (EURODIAB) register, which included 29,311 incident cases of type 1 diabetes in youth aged \<15 years recorded between 1989 and 2003, revealed regional differences in the trend of diabetes incidence \[[@pmed.1003052.ref008]\]. In areas with a high burden of type 1 diabetes, such as the Nordic countries, the United States, and Australia, the incidence appeared to have stabilised over the past decade \[[@pmed.1003052.ref009],[@pmed.1003052.ref010],[@pmed.1003052.ref011]\]. Conversely, the incidence of type 1 diabetes has continued to rise in places of low disease prevalence, including East Asia \[[@pmed.1003052.ref012],[@pmed.1003052.ref013]\]. Based on a registry of 622 newly diagnosed cases of type 1 diabetes in children aged \<15 years in Shanghai, Zhao and colleagues observed an increase in incidence from 1.5 per 100,000 person-years in 1997--2001 to 5.5 per 100,000 person-years in 2007--2011 \[[@pmed.1003052.ref012]\]. From the 2012--2014 National Health Insurance Service database containing 706 physician-reported cases of type 1 diabetes in children aged \<15 years in South Korea, Kim and colleagues reported an incidence of 3.2 per 100,000 person-years, which was 2.3-fold higher compared with the rate recorded in the earlier period of 1995--2000 \[[@pmed.1003052.ref013]\]. In the present study, we also detected an increase in the incidence of type 1 diabetes in children and adolescents, and the increase occurred in both sexes. In Hong Kong, the incidence of type 1 diabetes has not been determined since the last report 2 decades ago. Based on retrospective retrieval of 255 paediatric cases of newly diagnosed diabetes between 1984 and 1996, Huen and colleagues recorded an incidence of 1.4 per 100,000 person-years for type 1 diabetes in children aged \<15 years in Hong Kong, which was considerably lower than our updated estimates of 5.3--6.4 per 100,000 person-years in a comparable age group \[[@pmed.1003052.ref014]\]. Our observations, together with others' observations showing a similar rise in incidence, remain unexplained, although environmental factors, including obesity, nutrition, climate, and infection, have been implicated in the induction and acceleration of beta cell destruction \[[@pmed.1003052.ref015]\]. From surveys of Hong Kong school children, the prevalence of overweight or obesity rose from 11.6% in the mid-1990s to 16.7% in 2005 \[[@pmed.1003052.ref016]\], and the prevalence was 17.6% in primary school students and 19.9% in secondary school students in the last estimation in 2018 \[[@pmed.1003052.ref017]\]. It is noteworthy that although the incidence was the highest in the paediatric population, adults aged \>20 years accounted for two-thirds of the newly diagnosed cases in our database. In contrast to the rising trend of childhood-onset type 1 diabetes, the incidence of adult-onset type 1 diabetes has not increased.

Incidence of type 2 diabetes in youth and young adults {#sec017}
------------------------------------------------------

The growing number of young people acquiring type 2 diabetes is a major health concern that is now seen globally. In the present study, 60% of incident cases of diabetes in people aged \<20 years were type 2 diabetes. The SEARCH for Diabetes in Youth registry, which systematically identified and followed youth with diabetes in the US, reported an annual increase of 4.8% in the incidence of type 2 diabetes in people aged \<20 years between 2002 and 2012, from 7.0 to 9.0 per 100,000 person-years in boys and from 11.1 to 16.2 per 100,000 person-years in girls \[[@pmed.1003052.ref018]\]. Furthermore, the increase was larger in Asians and Pacific Islanders (annual increase 16.0%) than Europeans (annual increase 3.3%). Similarly, Wu and colleagues reported an increase in incidence from 0.7 to 3.6 per 100,000 person-years using a registry of 392 newly diagnosed cases of young-onset diabetes presented between 2007 and 2013 in Zhejiang, China \[[@pmed.1003052.ref019]\]. Among those aged \<20 years in Hong Kong, the average annual increase in incidence was 4.8%--5.9%, and the last recorded crude incidence rates in 2015 were 8.3 and 9.2 per 100,000 person-years in boys and girl, respectively, which were lower than the US figures but higher than rates in China. Similarly, we detected an increase in incidence of type 2 diabetes in people aged 20 to \<40 years in both sexes. Besides exposure to an increasingly obesogenic environment, intrauterine effects from gestational diabetes and/or maternal obesity and exposure to present-day endocrine disruptors may be responsible \[[@pmed.1003052.ref020]--[@pmed.1003052.ref022]\]. It is also possible that the observed incidence trend of young-onset type 2 diabetes was the result of people seeking medical attention earlier in their disease trajectory rather than an actual fall in the age of diabetes development. In this regard, people who would develop diabetes were diagnosed progressively earlier, thus removing people from the undiagnosed pool who would have otherwise presented at an older age.

Incidence of type 2 diabetes in middle-aged to older adults {#sec018}
-----------------------------------------------------------

In people aged 40 to \<60 years, the incidence of type 2 diabetes in both sexes initially increased and then flattened from 2011/2012 onward. In women aged ≥60 years, the incidence was stable until 2011 and declined thereafter, whereas in men aged ≥60 years, the incidence remained constant. The absence of a rise might reflect levelling off in exposure to risk factors. In Hong Kong, the prevalence of obesity has been stable in men and has declined in women since the mid-1990s \[[@pmed.1003052.ref023],[@pmed.1003052.ref024]\], which is attributable to a series of government-led health promotion initiatives targeting healthier lifestyles, such as the EatSmart programme and mandatory nutrition labelling during this period \[[@pmed.1003052.ref025]\]. Women are generally more receptive to health information and ready to adopt a healthy lifestyle compared with men, which might in part account for the sex difference in trends of obesity and type 2 diabetes \[[@pmed.1003052.ref026]\]. Cigarette smoking is linked to the development of type 2 diabetes \[[@pmed.1003052.ref027]\]. Antismoking advertising campaigns and government policy to ban smoking in many public areas have resulted in a reduction in smoking rates over the past 35 years, from 23.3% in 1982 to 10.0% in 2017 in Hong Kong \[[@pmed.1003052.ref028]\]. Lastly, saturation effect could be an explanatory factor, wherein increased health awareness and improved screening efforts during earlier periods have captured most of the high-risk individuals, thus depleting the pool of undiagnosed type 2 diabetes over time. In support of this, we observed a significant decline in HbA1c values at diagnosis of type 2 diabetes from 2002 to 2011, possibly reflecting proactive case finding and earlier detection. Although screening programmes for diabetes have not been formally introduced in Hong Kong, governmental policies to enhance primary care, including the dissemination of a reference framework for diabetes care, could have an effect toward improving diabetes detection \[[@pmed.1003052.ref029],[@pmed.1003052.ref030]\]. The increasing number of outpatient and inpatient attendances to public healthcare facilities over time also supports an increasing opportunity for diagnosing diabetes \[[@pmed.1003052.ref031]\].

Limited studies indicated interethnic variation in the risks for type 2 diabetes. Alangh and colleagues reported 10-year secular trends in diabetes incidence in Ontario, Canada, and found that incidence increased moderately by 24% in the European population as compared with a 15-fold increase in the Chinese population, in which the absolute incidence rate was twice that of Europeans (19.6 versus 10.0 per 1,000 person-years) by 2005 \[[@pmed.1003052.ref032]\]. From contemporary studies, the age- and sex-adjusted diabetes incidence rates among adults were 370 per 100,000 person-years in the United Kingdom \[[@pmed.1003052.ref033]\], 398 per 100,000 person-years in Sweden \[[@pmed.1003052.ref034]\], and 710 per 100,000 person-years in the US during the 2012--2014 period \[[@pmed.1003052.ref035]\]. Over a comparable reporting period, the rates were 1,099 and 949 per 100,000 person-years in men and women in our study, 830 per 100,000 person-years in Korea \[[@pmed.1003052.ref036]\], and 800 per 100,000 person-years in Taiwan \[[@pmed.1003052.ref037]\]. Differences in methods used to capture incident cases and diagnostic intensities would have influenced the estimates. Allowing for these factors, available data, including those from the present study, suggest that the incidence of type 2 diabetes may be higher in East Asians than Europeans. Although Chinese people are leaner than Europeans, for the same BMI, the former have more visceral fat, greater insulin resistance, and more metabolic complications \[[@pmed.1003052.ref038]\]. Moreover, low body weight is linked to poorer pancreatic beta cell reserve, and Chinese people are more vulnerable to external factors, such as glucolipotoxicity, that trigger progressive decline in beta cell function \[[@pmed.1003052.ref039]\].

Transient rise in the number of diabetes cases in 2004 {#sec019}
------------------------------------------------------

A sharp peak in the incidence of type 2 diabetes was recorded in 2004, and this could be connected to the severe acute respiratory syndrome epidemic in 2003 in Hong Kong \[[@pmed.1003052.ref040]\]. The excess of 21,000 new cases of type 2 diabetes in 2004 compared with 2003 might be due to heightened health vigilance at the aftermath of the epidemic, which prompted increased doctor visits. The modest dip in the number of new cases in the ensuing 3 years (from 2005 to 2007) compared with numbers between 2002 and 2003 could support earlier identification of cases during the transitory period, leaving fewer cases to be detected in subsequent years. The excess might also represent an injection of prevalent cases from the private sector to the public system in response to economic adversity.

Limitations {#sec020}
-----------

We acknowledge the following limitations in the study. An electronic medical record database was used to identify patients with diabetes, and we cannot exclude the possibility of incomplete capture. The data source included patients who attended only public healthcare facilities, and those receiving care in the private sector---who represent about 10% of the entire disease population---were not included. As such, the incidence rates as reported were likely underestimations of the actual figure by up to 10%. However, except for 2004, there was no evidence that the ratio of medical care in private sector versus public sector has changed over time, and therefore, this is unlikely to affect assessment of incidence trends. Two-hour plasma glucose by an oral glucose tolerance test (OGTT) was not included as one of the qualifying criteria for diabetes, which could also underestimate incidence rates, especially in the paediatric population in whom HbA1c alone has low sensitivity of diagnosing type 2 diabetes \[[@pmed.1003052.ref041]\]. The categorisation of type 1 and type 2 diabetes was based on an algorithm rather than direct inspection of the clinical notes. Although the algorithm was developed in an independent data set in which the diagnosis of type 1 diabetes was verified by reviewing medical records, the absence of confirmatory tests such as anti-islet cell antibodies or C-peptide levels could lead to incorrect differentiation of type 1 and type 2 diabetes, affecting the accuracy of the algorithm. Misclassifying type 2 as type 1 diabetes would significantly inflate the incidence of type 1 diabetes, whereas the impact on incidence of type 2 diabetes was probably minimal. The probability of incorrect grouping would be greater in older patients in whom the algorithm performed less well, and estimates of incidence of type 1 diabetes in adults will require confirmation in other cohorts. Because of limitations in details of the extracted information, we could not discern patients with other aetiologies of diabetes, such as maturity-onset diabetes of the young and secondary diabetes. Owing to the asymptomatic nature of diabetes, diagnosis is often delayed. Despite the good quality of the surveillance database, undiagnosed cases could not be captured, leading to underreporting of case burden. The recorded incidence rates were also sensitive to secular changes in people's health-seeking behaviour, screening practice, and prescription behaviour.

Summary {#sec021}
-------

In this report on the secular trend of the incidence of diabetes in Hong Kong, we revealed that the incidence of type 1 diabetes increased in people aged \<20 years and was stable in other age groups. The incidence of type 2 diabetes also increased in people aged \<40 years and accounted for over half of new cases of diabetes among people aged \<20 years. In people aged ≥40 years, the incidence of type 2 diabetes remained constant. These observations provide an impetus for scaling up measures to prevent development of diabetes in people at risk.

Supporting information {#sec022}
======================

###### Number of people with incident and prevalent type 1 or type 2 diabetes in the Hong Kong Diabetes Surveillance Database, 2002--2015.

(DOCX)

###### 

Click here for additional data file.

###### Demographic and clinical characteristics of people with incident type 1 or type 2 diabetes at diagnosis in the Hong Kong Diabetes Surveillance Database, 2002--2015.

(DOCX)

###### 

Click here for additional data file.

###### Description of the Hong Kong Diabetes Surveillance Database, 2002--2015.

(TIF)

###### 

Click here for additional data file.

###### Number of new cases of type 2 diabetes by year in the Hong Kong Diabetes Surveillance Database, 2002--2015.

(TIF)

###### 

Click here for additional data file.

###### Incidence trends of type 2 diabetes in men and women using restricted cubic spline, 2002--2015.

\(A\) Incidence trends of type 2 diabetes in boys aged \<20 years using restricted cubic spline. (B) Incidence trends of type 2 diabetes in men aged 20 to \<40 years using restricted cubic spline. (C) Incidence trends of type 2 diabetes in men aged 40 to \<60 years using restricted cubic spline. (D) Incidence trends of type 2 diabetes in men aged ≥20 years using restricted cubic spline. (E) Incidence trends of type 2 diabetes in girls aged \<20 years using restricted cubic spline. (F) Incidence trends of type 2 diabetes in women aged 20 to \<40 years using restricted cubic spline. (G) Incidence trends of type 2 diabetes in women aged 40 to \<60 years using restricted cubic spline. (H) Incidence trends of type 2 diabetes in women aged ≥20 years using restricted cubic spline.

(TIF)

###### 

Click here for additional data file.

###### Mean HbA1c levels at diagnosis in men and women with incident type 2 diabetes between 2002 and 2015.

HbA1c, glycated haemoglobin.

(TIF)

###### 

Click here for additional data file.

###### STROBE, Strengthening the Reporting of Observational Studies in Epidemiology.

(DOC)

###### 

Click here for additional data file.

We acknowledge the Hong Kong Hospital Authority for providing the data for research.

AAPC

:   average APC

APC

:   annual percentage change

EURODIAB

:   European Diabetes

FPG

:   fasting plasma glucose

HA

:   Hospital Authority

HbA1c

:   glycated haemoglobin

HKDR

:   Hong Kong Diabetes Register

HKDSD

:   Hong Kong Diabetes Surveillance Database

ICD-9

:   *International Classification of Diseases*, *Ninth Revision*

NPV

:   negative predictive value

OGTT

:   oral glucose tolerance test

PPV

:   positive predictive value
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7 Sep 2019

Dear Dr. Luk,

Thank you very much for submitting your manuscript \"Trends on incidence of type 1 and type 2 diabetes in Hong Kong, China: Analysis of the Hong Kong Diabetes Surveillance Database\" (PMEDICINE-D-19-01907) for consideration at PLOS Medicine.

Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

\[LINK\]

In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers\' and editors\' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: <http://journals.plos.org/plosmedicine/s/figures>. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <PLOSMedicine@plos.org>.

We expect to receive your revised manuscript by Sep 23 2019 11:59PM. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: <http://journals.plos.org/plosmedicine/s/competing-interests>.

Please use the following link to submit the revised manuscript:

<https://www.editorialmanager.com/pmedicine/>

Your article can be found in the \"Submissions Needing Revision\" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-methods>.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Clare Stone, PhD, Acting Editor-in-Chief

for

Adya Misra

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from the editors:

We note there are some substantial issues to be resolved as highlighted by the referees. Please also address the following points:

Title -- I wonder if a clearer study design could be used for the 2nd part of the title?

Abstract -- there should be 3 sections: Background, Methods and Findings, Conclusions- please recast; Please quantify any results related to data with 95%Cis and p values; please provide a sentence on the limitations of the study as the final sentence of the 'Methods and Findings section; please do add some summary level demograhic information;

Data -- you say that no access is allowed -- not even for users who meet requirements?

At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: <https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary>

Please use square brackets for refs in the main text.

Line 113 -- type 1 or 2?

Line 167 -- please define diabetes codes

Line 177- define how diabetes is defined -- what measure?

Line 199- I am confused by this sentence. Please clarify 'Of 778,051 people captured in the HKDSD, we excluded 33,916 people with diabetes codes but not fulfilled other criteria of diabetes.'

Throughout you tend to fall back on describing simply diabetes, as this paper is about type 1 and 2, please be careful to always state which(or if both)

The word youth seems a little odd, please instead say people under 20 years of age

Figure 1 -- can I suggest you use different colours instead of 3 variations of blue

Please use the \"Vancouver\" style for reference formatting, and see our website for other reference guidelines <https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references>. For example 6 names and then et al.

Mian text -- is it possible to provide some information perhaps in table for -- adding to one of the current tables -- with more participant characteristics, eg BMI, married, smoking etc...

Please provide a STROBE reporting checklist

Do you have a prespecified analysis plan, if so please provide as a Supp file and a call out in the methods to it. If no plan exists, please state when the analyses were planned in relation to data analysis.

Comments from the reviewers:

Reviewer \#1: I confine my remarks to statistical aspects of this paper. Unfortunately, I have some major issues that need to be resolved before I can recommend publication.

First, joinpoint analysis needs to be described and its use needs to be justified. It\'s a fairly obscure method and I had trouble finding literature describing it, but it appears to be a restricted linear spline method. However, while I do like the use of spline models, there are reasons to prefer restricted cubic splines. And spline methods are a) Well known and b) Implemented in popular software including R and SAS, rather than relying on specialized software.

Second, the results of the regression analysis don\'t seem to be included. Are the figures the results of the analysis? Are there other results? What about parameter estimates?

Third, categorizing age is almost surely a mistake. Use age as \"number of years\".

More specific comments:

Line 169 - 173 Something very strange is happening here. Perfect results for under 20 and then really bad results for over 20 make me suspicious that something is going wrong somewhere or, perhaps there are very few people under 20 with type I diabetes, which could lead to overfitting. The authors note that 103 people in HKDR had type I and it seems like about 1/3 were under 20 (although this doesn\'t seem to be explicitly stated).

Line 210 and other places. The authors state that many trends were linear, apparently from testing a model that had year as a linear effect on rate. But the fact that a linear trend is statistically significant does not mean the trend was linear, it just just means a straight line is a better fit than a null model. The tables and the graphs show that the trends were not linear at all - they went up and down in a complex pattern.

Table 1 may not be needed. It seems to duplicate the material from the graphs, which are easier to interpret. If Table 1 is kept, then the AAPC and the p value should be removed - they are misleading.

The age categories for the figures don\'t match the age caegories for the table - it\'s unclear why not, or what was actually included in the model - age as 0-20, 20-40 etc or age as 0-4, 5-9 etc or age as integer or what.

Peter Flom

Reviewer \#2: This is a well written and clear paper that is of importance understanding diabetes epidemiology in this region of the world.

I have a number of recommendations to improve the manuscript.

1\. Study population line 129. Please comment in limitations section further about diagnosing diabetes by HbA1c alone in chidlren. Please see Nowicka P, Santoro N, Liu H et al (2011) Utility of hemoglobin A(1c) for diagnosing prediabetes and diabetes in obese children and adolescents. Diabetes Care 34: 1306-11

2\. Study population line 135. Please comment about why 1 day was chosen, is this sufficient time for a diagnosis of diabetes to be made e.g. revised diagnosis and subsequently drugs quickly stopped?

3\. Study population line 159. Please comment specifically in the limitations section about the lack of islet cell antibodies for diagnosising T1DM in children. This is often crucial to distinguish T1 from T2 in children especially in absence of c peptide/insulin and in a population of T1 who may be increasingly overweight. Please see diagnosistic criteria used for T2DM in this recent study Candler TP, Mahmoud O, Lynn RM et al (2018a) Continuing rise of type 2 diabetes incidence in children and young people in the UK. Diabet Med 35: 737-44.

4\. Figure 2 needs revising to better display the rising incidence in \<20 year olds. In the current graph, the scale for this age group is not useful to see any change in trend. Suggest split figures for \>20 and \<20 to better show change incidence. This is a major finding in your study but is not displayed clearly in the results.

5\. Line 285. Please expand further in the discussion as the cause of a reduction in incidence in women \>60, can the authors speculate or suggest from other studies a cause for this?

6\. Line 293. Please comment further regarding lower HbA1c at diagnosis across the time period 2002-2011 - is this statistically significant i.e. can you provide a p value/statistical test? Was there a specific public health campaign across this period suggesting people present earlier or a screening programme introduced? Please speculate as the the cause of this further in the discussion.

Reviewer \#3: The author used national wide data to estimate trends of incidence of diabetes types. They could also look into prevalence of diabetes.

The authors presented data in adults and younger groups, it would be good to separately present data in adults and young adults and children

What are key drivers for such trends? The authors might have access to clinical information (e.g. BMI) and other sociodemographic data to investigate these?

Also it would be useful to provide diabetes incidence projection and possibly to calculate the burden attributable to diabetes (DALY) in this country.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003052.r002

Author response to Decision Letter 0

18 Oct 2019

###### 

Submitted filename: Response to Reviewers_PLOSMED CK.docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1003052.r003
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18 Dec 2019

Dear Dr. Luk,

Thank you very much for re-submitting your manuscript \"Secular trends on incidence of type 1 and type 2 diabetes in Hong Kong\" (PMEDICINE-D-19-01907R1) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by xxx reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Dec 23 2019 11:59PM.

Sincerely,

Clare Stone, PhD

Managing Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

Title- in order to adhere to PLOS Medicine style guide, your title must contain a study descriptor. Please revise to "Secular trends on incidence of type 1 and type 2 diabetes in Hong Kong: a retrospective cohort study"

Data availability- The Data Availability Statement (DAS) requires revision. For each data source used in your study: a) If the data are freely or publicly available, note this and state the location of the data: within the paper, in Supporting Information files, or in a public repository (include the DOI or accession number). b) If the data are owned by a third party but freely available upon request, please note this and state the owner of the data set and contact information for data requests (web or email address). Note that a study author cannot be the contact person for the data. c) If the data are not freely available, please describe briefly the ethical, legal, or contractual restriction that prevents you from sharing it. Please also include an appropriate contact (web or email address) for inquiries (again, this cannot be a study author).

Abstract- 95% CI is okay, we do not need the words "confidence interval" as this is a standard term

Abstract line 81 should be "subject" not "subjected"

Abstract conclusions- both sentences are very similar and there is no indication what is meant by youth, young adults or older adults. Please specify age groups and could it be rephrased to "There was an increase in incidence of both Type 1 and Type 2 diabetes between the age of \_ and \_ but remained stable in the age group \_\_ ".

Author summary please reword "over half is coming from Asia" to "over half of the diabetes population come from Asian countries" or similar

Author summary- please remove " calls for preventative actions ..." as your study determined the trends and the significance of your findings needs a better explanation

Introduction- I don't think we have a Type 2 diabetes pandemic. I appreciate the rates are increasing and there are public health concerns but please tone down.

Introduction- please change "over-weight" to "overweight"

Methods- please mention earlier in the methods section whether your study had a prospective analysis plan. If not, please provide reasons

Page 24 Line 414- please remove the word "destined" and consider more appropriate language for a scientific article

Page 24 please provide a reference to support "women are generally more receptive..."

Please ensure you use consistent terminology for ethnicity throughout the text- such as "east Asian" or "Chinese" as they are both used interchangeably.

Page 27, please consider revising the limitation section to remove the words "firstly" "fifthly" etc as these are not appropriate for a research article

Throughout the text, when you say older or younger adults please add the age group referred to for additional clarity

Line 161 -- does this need updating? 250.xx

Line 429 "marked reduction" -- please be more specific and give a %decline

The STROBE checklist cannot contain page or line numbers as these change during the publication process. Please reference the appropriate paragraphs/sections

Comments from Reviewers:

Reviewer \#1: The authors have addressed my concerns and I now recommend publication.

Peter Flom

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003052.r004
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22 Jan 2020

Dear Dr Luk,

On behalf of my colleagues and the academic editor, Dr. Sanjay Basu, I am delighted to inform you that your manuscript entitled \"Secular trends in incidence of type 1 and type 2 diabetes in Hong Kong: a retrospective cohort study\" (PMEDICINE-D-19-01907R2) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

[^1]: RCWM acknowledges receiving research support (outside of this work) from AstraZeneca, Bayer, Pfizer for conducting clinical trials and honoraria or consultancy fees from AstraZeneca and Boehringer Ingelheim, all of which has been donated to the Chinese University of Hong Kong to support diabetes research. RCWM is a member of the Editorial Board of PLoS Medicine. AOYL acknowledges receiving research support (outside of this work) from Boehringer Ingelheim, MSD, Sanofi, Amgen and travel grants from travel grant from AstraZeneca, Boehringer Ingelheim, MSD, Novartis, Novo Nordisk, Sanofi. JCNC and RCWM are cofounders of GemVCare, a diabetes genetic testing laboratory, which was established through support from the Technology Start-up Support Scheme for Universities (TSSSU) from the Hong Kong Government Innovation and Technology Commission (ITC).
